Here, we validated a novel anti-cancer therapeutic potency of the combined treatment with small molecules LCL161 and ABT-263 and relevant molecular mechanisms through the necrosome complex in tyrosine aminoacyl-tRNA synthetase (YARS)-positive breast cancer. This evidence concerns the gene YARS1 and breast cancer.